Ata Ppgl Genetic Variant Treatment Algorithm

---
name: ata-ppgl-genetic-variant-treatment-algorithm
description: This skill selects a treatment algorithm for pheochromocytoma and paraganglioma based on identified germline pathogenic variants, enabling personalized management per syndrome-specific guidelines. It is triggered when a clinician identifies RET, VHL, NF1, or SDHx pathogenic variants and asks how genetic results should change management.
---

# Select treatment algorithm based on genetic pathogenic variants in pheochromocytoma and paraganglioma

## STEP 1 — Gather Information
Collect germline genetic test results (RET, VHL, NF1, SDHx) and clinical data: number of lesions, adrenal vs. extra-adrenal location, presence of metastasis, and syndromic features (e.g., medullary thyroid carcinoma, hemangioblastoma, café-au-lait spots).

## STEP 2 — Rule In / Rule Out
Is the pathogenic variant in RET, VHL, or NF1? If yes, proceed to syndrome-specific pathway; if no, proceed to SDHx pathway.

## STEP 3 — Classify or Stratify
For RET/VHL/NF1: classify by syndrome and follow respective guideline-recommended surveillance (e.g., MEN2, VHL, NF1). For SDHx: stratify by clinical characteristics—multiple/extra-adrenal lesions or high metastasis risk versus solitary adrenal lesion with low risk.

## STEP 4 — Decide
For RET/VHL/NF1: implement syndrome-specific surveillance (e.g., annual plasma metanephrines, neck ultrasound, abdominal MRI) and consider prophylactic surgery per syndrome guidelines. For SDHx: if multiple/extra-adrenal lesions or high metastasis risk, obtain intensified imaging (68Ga-DOTATATE PET/MRI) and discuss PRRT/temozolomide/sunitinib (off-label); if low risk, standard biochemical and imaging follow-up every 1–2 years.

## Clinical Guardrails / Mimics / Pitfalls
Do not neglect surveillance for SDHx carriers even if initial imaging is negative; avoid invasive procedures based solely on variant without clinical correlation; remember to offer genetic testing and counseling to first-degree relatives; do not assume all SDHx variants confer equal metastasis risk—correlate with phenotype.

## Concrete Clinical Example
A 34-year-old with left adrenal pheochromocytoma is found to have a RET codon 634 pathogenic variant. Management follows MEN2 guidelines: annual plasma metanephrines, neck ultrasound for medullary thyroid carcinoma, and discussion of prophylactic thyroidectomy; abdominal MRI biennially to monitor for bilateral or extra-adrenal lesions.

**Source:** Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165